New drug ARC101 enters first human tests for Hard-to-Treat cancers
NCT ID NCT06672185
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new drug called ARC101 in 70 people with advanced solid tumors that have a specific marker (Claudin 6). The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. Participants must have ovarian, testicular, or other Claudin 6-positive cancers that have not responded to standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARC101
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that are Claudin 6 positive.
What could go wrong
This is a very early, first-in-human study with only 70 participants. The drug may not be effective or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BC Cancer Research Centre
RECRUITINGVancouver, British Columbia, V5Z 0B4, Canada
Contact
-
Cabrini Health Research
RECRUITINGMalvern, Victoria, 3144, Australia
Contact
-
Cancer Research SA
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
-
McGill University Health Centre
RECRUITINGMontreal, Quebec, H4A 0B1, Canada
Contact
-
Rambam Medical Center
RECRUITINGHaifa, 3109601, Israel
Contact
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact
-
START San Antonio, LLC.
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
-
Sheba Medical Center
RECRUITINGRamat Gan, 52621, Israel
Contact
-
Sourasky Medical Center
RECRUITINGTel Aviv, 6423906, Israel
Contact
-
Sunshine Coast University Private Hospital
RECRUITINGBirtinya, Queensland, 4575, Australia
Contact
-
The Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2C4, Canada
Contact